Supernus Pharmaceuticals ... (SUPN)
31.69
0.02 (0.06%)
At close: Apr 14, 2025, 1:14 PM
0.06% (1D)
| Bid | 31.5 |
| Market Cap | 1.77B |
| Revenue (ttm) | 661.82M |
| Net Income (ttm) | 73.86M |
| EPS (ttm) | 1.32 |
| PE Ratio (ttm) | 24.01 |
| Forward PE | 20.65 |
| Analyst | Hold |
| Ask | 31.87 |
| Volume | 152,512 |
| Avg. Volume (20D) | 614,478 |
| Open | 32.12 |
| Previous Close | 31.67 |
| Day's Range | 31.48 - 32.27 |
| 52-Week Range | 25.53 - 40.28 |
| Beta | 0.90 |
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy tr...
Sector Healthcare
IPO Date May 1, 2012
Employees 674
Stock Exchange NASDAQ
Ticker Symbol SUPN
Website https://www.supernus.com
Analyst Forecast
According to 2 analyst ratings, the average rating for SUPN stock is "Hold." The 12-month stock price forecast is $36, which is an increase of 13.60% from the latest price.
Stock ForecastsNext Earnings Release
Supernus Pharmaceuticals Inc. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-15.67%
Supernus Pharmaceuticals shares are trading lower ...
Unlock content with
Pro Subscription
1 month ago
+1.64%
Supernus Pharmaceuticals shares are trading lower after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.
